New drug trial targets Tough-to-Treat uterine cancer
NCT ID NCT02491099
Summary
This study is testing whether the drug afatinib can help control a specific type of aggressive uterine cancer that has returned or persisted after previous treatments. It will enroll about 50 women whose cancer tests positive for a protein called HER2. The main goal is to see if patients can live without their cancer getting worse for at least six months after starting the medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2/NEU+ UTERINE SEROUS CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
COMPLETEDBoston, Massachusetts, 02114, United States
-
University of Arizona Cancer Center
COMPLETEDTucson, Arizona, 85724, United States
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.